Research programme: antisense drug therapies - Ionis/Xenon

Drug Profile

Research programme: antisense drug therapies - Ionis/Xenon

Alternative Names: XEN 701

Latest Information Update: 24 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Xenon Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Hepcidin inhibitors; HFE2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 10 Jun 2013 XEN 701 licensed to Xenon Pharmaceuticals worldwide
  • 10 Jun 2013 Preclinical trials in Anaemia in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top